Introduction
attention-deficit/hyperactivity disorder, ADHD
SPENCER, GROWTH SUPPRESSION
Methylphenidate (MPH) is a commonly prescribed medication for attention-deficit/hyperactivity disorder (ADHD) because of its efficacy for symptom reduction and overall favorable safety record. MPH is often prescribed for long-term use in patients with ADHD (Storebø et al. This formulation of SDX/d-MPH (Azstarys™; Corium, LLC, Boston, MA) was approved by the US Food and Drug Administration for patients aged 6 years and older with ADHD.In a pivotal, randomized, placebo-controlled, double-blind laboratory classroom study of children with ADHD, SDX/d-MPH treatment was shown to significantly improve ADHD symptoms compared with placebo (Kollins et al. A subsequent, 1-year, open-label safety study of SDX/d-MPH in children with ADHD showed that SDX/d-MPH was well tolerated and had sustained efficacy during the 1-year treatment period (Childress et al. Long-term treatment with stimulants, such as MPH for ADHD, in children has been associated with modest slowing of growth velocity and prescribing information for these treatments warns of long-term growth suppression, which can cause concern and limit their use (Spencer et al. 